Cancer Res Treat.  2005 Aug;37(4):208-211.

A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer

• Lee WS
• Lee GW
• Kim HW
• Lee OJ
• Lee YJ
• Ko GH
• Lee JS
• Jang JS
• Ha WS

Abstract

PURPOSE
Heptaplatin (SKI-2053 R) is a new platinum analogue, with a better toxicity profile than cisplatin, and has antitumor activity even in cisplatin resistant cell lines. 5-fluoruracil (5-FU) has shown synergy with platinum compounds. This phase II trial was designed to determine the efficacy and toxicities of heptaplatin/ 5-FU (5-fluorouracil) for treating stomach cancer. MATERIALS AND METHODS: Thirty-two patients with advanced, measurable gastric adenocarcinomas were enrolled in this trial. The treatment consisted of heptaplatin, 400 mg/m2/day (1 hour IV infusion), on day 1 and 5-FU, 800 mg/m2/day (12 hours IV infusion), on days 1 to 5. The cycles were repeated every 3 weeks. RESULTS: Of the 26 evaluable patients, 9 had partial responses and 1a complete response (overall response rate, 38%; 95% confidence interval, 19~57%). The median response duration was 23 weeks (range: 4~60 weeks). The median time to progression was 26 weeks (range: 3~68 weeks). The grades III-IV toxicities were mostly hematological toxicities: leucopenia was observed in 11 patients (35%) and thrombocytopenia 4 (13%). No definite neuropathy was observed. Grade I-II nephropathy was also noted: grade I high BUN/creatinine levels occurred in 5 patients (16%), grade II proteinuria 2 (6%), grade I proteinuria 5 (16%). Neutropenic fever developed in 5 patients (16%) and 1 died of pneumonia in a neutropenic state. CONCLUSION: This study suggests that the regimen of Heptaplatin/5-FU should be effective and have a favorable toxicity profile for the patients suffering with advanced stomach cancer.

Keyword

Stomach neoplasms; Heptaplatin (SKI-2053 R); 5-FU; Chemotherapy

MeSH Terms

Adenocarcinoma
Cell Line
Cisplatin
Drug Therapy
Fever
Fluorouracil
Humans
Leucovorin*
Platinum
Platinum Compounds
Pneumonia
Proteinuria
Stomach Neoplasms*
Stomach*
Thrombocytopenia
Cisplatin
Fluorouracil
Leucovorin
Platinum
Platinum Compounds

Figure

• 

  Fig. 1 Kaplan-Meier estimates of the time to progression of the patients with advanced gastric cancer. The median time to progression was 15 weeks (range: 3~85 weeks).

Reference

1. Karpen MS, Kelsen DP, Tepper JE. Devita VT, Hellman S, Rosenberg SA, editors. Cancer of the stomach. Cancer: principles and practice of oncology. 2001. Philadelphia: Lippincott-Raven;p. 1092–1126.

2. Bae JM, Won YJ, Jung KW, Suh KA, Ahn DH, Park JG. Annual report of the central cancer registry in Korea - 1999: Based on registered data from 128 hospitals. Cancer Res Treat. 2001; 33:367–372.

3. Kim JP, Yu HJ, Lee JH. Results of immunochemo-surgery for gastric carcinoma. Hepatogastroenterology. 2001; 48:1227–1230. PMID: 11677936.

4. Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wieand HS. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol. 1986; 4:1053–1057. PMID: 3014083.

5. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol. 1991; 2:751–754. PMID: 1801881.

6. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993; 71:3813–3818. PMID: 8508349.

7. Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, et al. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother Pharmacol. 1995; 35:441–445. PMID: 7850928.

8. Kim DK, Kim HT, Cho YB, Kim TS, Kim KH, Hong WS. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane) platinum (II). Anticancer Res. 1996; 16:251–256. PMID: 8615617.

9. Kim NK, Im SA, Kim DW, Lee MH, Jung CW, Cho EK, et al. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer. 1999; 86:1109–1115. PMID: 10506693.

10. Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wieand HS. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol. 1986; 4:1053–1057. PMID: 3014083.

11. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin Trials. 1989; 10:1–10.

12. Lin YC, Chen JS, Wang CH, Wang HM, Chang HK, Liaul CT, et al. Weekly high-dose 5-fluorouracil (5-FU), leucovorin (LV) and bimonthly cisplatin in patients with advanced gastric cancer. Jpn J Clin Oncol. 2001; 31:605–609. PMID: 11902492.

13. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol. 2003; 14:383–387. PMID: 12598342.

14. Ai-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004; 22:658–663. PMID: 14966088.

15. Ahn JH, Kang YK, Kim TW, Bahng H, Chang HM, Kang WC, et al. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother Pharmacol. 2002; 50:104–110. PMID: 12172973.

16. Oh SC, Yoon SY, Seo JH, Choi CW, Kim BS, Shin SW, et al. Pilot study of heptaplatin, UFT-E and leucovorin in advanced gastric carcinoma. Cancer Res Treat. 2003; 35:117–122.